Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors

Journal of Cutaneous Pathology

Volumn 40, Issue 10, 2013, Pages 865-870

  Brodell, Lindsey A ^a   Hepper, Donna ^b   Lind, Anne ^a   Gru, Alejandro A ^a   Anadkat, Milan J ^a  

^a BARNES JEWISH HOSPITAL   (United States)

^b Skin Care Specialty Physicians   (United States)

Author keywords

dermatology; dermatopathology; hair follicle

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ACNEIFORM ERUPTIONS; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; PATHOLOGY; ACNE; ARTICLE; DERMATOLOGY; DRUG ANTAGONISM; HAIR FOLLICLE; SKIN DISEASE;

ACNEIFORM ERUPTIONS; AGED; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

DERMATOLOGY; DERMATOPATHOLOGY; HAIR FOLLICLE;

EID: 84884908046     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12202     Document Type: Article

References (16)

1. Baas J, Krens LL, Guchelaar HJ, et al. Recommendations on management of EGFR inhibitor-induced skin toxicity: a systematic review. Cancer Treat Rev 2012; 38: 505.
2. Wagner L, Lai SE, Aneja M, et al. Development of a functional assessment of side-effects to therapy (FAST) questionnaire to assess dermatology-related quality of life in patients treated with EGFR inhibitors (EGFRI): The FAST-EGFRI. J Clin Oncol 2007; 25 (18s): Abstr. 19532.
3. Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H,. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007; 43: 845.
4. Woodworth CD, Michael E, Marker D, Allen S, Smith L, Nees M,. Inhibition of the epidermal growth factor receptor increases expression of genes that stimulate inflammation, apoptosis, and cell attachment. Mol Cancer Ther 2005; 4: 650.
5. Segaert S, van Cutsem E,. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425.
6. Jost M, Karl C, Rodeck U,. The EGF receptor: an essential regulator of multiple epidermal functions. Eur J Dermatol 2001; 10: 505.
7. Blanchini D, Jayanth A, Chua Y, Cunningham D,. Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment and its potential role as a predictive marker. Clin Colorectal Cancer 2008; 7: 33.
8. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22: 3238.
9. Soulieres D, Senzer NN, Vokes EE, Hidalgo M, Agarwala SS, Siu LL,. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77.
10. Cohen EE, Rosen F, Stadler WM, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003; 21: 1980.
11. Heinemann V,. Targeted therapy of pancreatic cancer: predictors of response. Tumor Biol 2010; 31: S13.
12. Parma JM, Pavlick AC, Chang JCN, Rimawi MF, Trivedi MV,. Acneiform rash does not predict response to neoadjuvant lapatinib in breast cancer patients. Pharmacotherapy 2011; 31: 10.
13. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC,. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144: 1169.
14. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20: 110.
15. Nardone B, Nicholson K, Newman M, et al. Histopathological and immunohistochemical characterization of rash to human epidermal growth factor receptor 1 (HER1) and HER 1/2 inhibitors in cancer patients. Clin Cancer Res 2010; 16: 1.
16. Guttman-Yassky E, Mita A, De Jonge M, et al. Characterization of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib. Eur J Cancer 2010; 46: 2010.